Clinical Profile of Psoriasis Patients With Comorbid Fatty Liver and Risk Factors for Advanced Liver Fibrosis in Those With Metabolic Dysfunction–Associated Steatotic Liver Disease Hidenori Watabe, Tomomitsu Miyagaki, Kaori Nakajima, Ken Go, Tatsuro Okano, Takafumi Kadono The Journal of Dermatology.2026; 53(2): 237. CrossRef
Hepatic Safety of IL-17 Inhibitors in Psoriasis and Psoriatic Arthritis: A 12-Month Retrospective Cohort Evaluation Using the FIB-4 Index Umut Bakay, Tugba Izci Duran, Ozge Sevil Karstarli Bakay, Rahime Ekmekcioglu Dermatology Practical & Conceptual.2026; 16(1): 6746. CrossRef
Effects of Biologics on Fibrosis-4 Index in Patients with Psoriasis Takashi Morita, Susumu Ichiyama, Michiko Ito, Saeko Ozaki, Taeang Arai, Masanori Atsukawa, Katsuhiko Iwakiri, Teppei Hagino, Toshihiko Hoashi, Naoko Kanda, Hidehisa Saeki Journal of Nippon Medical School.2025; 92(1): 88. CrossRef
Effects of Guselkumab on the FIB‐4 Index in Psoriasis Patients (EGIPT): A Three‐Year Study Edoardo Mortato, Lorenzo Marcelli, Lorenzo Tofani, Alfredo Belcastro, Marina Talamonti, Claudia Paganini, Cosimo Di Raimondo, Luca Bianchi, Marco Galluzzo The Journal of Dermatology.2025; 52(6): 1113. CrossRef
MASLD and liver fibrosis in patients with psoriasis receiving IL-17 or IL-23 inhibitors: a systematic review José González Fernández, Lucía Prieto-Torres, Mariano Ara Martín, Samuel J. Martínez-Domínguez Therapeutic Advances in Gastroenterology.2025;[Epub] CrossRef
Hub Genes Involved in the Progression of Nonalcoholic Fatty Liver Disease to Hepatocellular Carcinoma Baiyi Liu, Xiaoxiao Wang, Nan Wu, Feng Liu, Huiying Rao Current Medicinal Chemistry.2025; 32(23): 4786. CrossRef
The Intriguing Roles of Cytokines in Metabolic Dysfunction-Associated Steatotic Liver Disease: A Narrative Review Ilias D. Vachliotis, Stergios A. Polyzos Current Obesity Reports.2025;[Epub] CrossRef
Relación entre el control de la psoriasis y la enfermedad hepática esteatósica asociada a disfunción metabólica Citlalli Guadalupe Hernández Guzmán, Blanca Elena Verazaluce Rodríguez, Lauro Fabián Amador Medina, Graciela López Mata, Erick Josefat Díaz Huerta, Óscar Noel Chávez Hernández Piel.2025; 40(9): 558. CrossRef
Biologic Therapy and Malignancy Risk in Psoriasis: A Retrospective Cohort Study Saori Takamura, Souichiro Saito, Sora Sugai, Yuki Shiko, Takumi Yamaguchi, Yohei Kawasaki, Tomoo Fukuda The Journal of Dermatology.2025; 52(12): 1796. CrossRef
FIB-4 as an effective screening tool in psoriatic arthritis patients at high-risk for liver disease: a cross-sectional study using FibroScan Katya Meridor, Stephanie R Harrison, Richard Parker, Chenchu Chimakurthi, Philip M Laws, Dennis McGonagle, Andrew Barr, Claire Y Vandevelde, Helena Marzo-Ortega, Jane E Freeston Rheumatology.2025;[Epub] CrossRef
Bimekizumab safety in moderate to severe plaque psoriasis: Rates of hepatic events and changes in liver parameters over 2 years in randomized phase 3/3b trials Mark Lebwohl, Joseph F. Merola, Bruce Strober, April Armstrong, Ayumi Yoshizaki, Paolo Gisondi, Balint Szilagyi, Luke Peterson, Dirk de Cuyper, Nancy Cross, Owen Davies, Alice B. Gottlieb Journal of the American Academy of Dermatology.2024; 91(2): 281. CrossRef
Interleukin‐23 inhibitors decrease Fibrosis‐4 index in psoriasis patients with elevated Fibrosis‐4 index but not interleukin‐17 inhibitors Ryosuke Takeshima, Masahiro Kamata, Shoya Suzuki, Makoto Ito, Ayu Watanabe, Hideaki Uchida, Chika Chijiwa, Yoshiki Okada, Saori Azuma, Mayumi Nagata, Shota Egawa, Azusa Hiura, Saki Fukaya, Kotaro Hayashi, Atsuko Fukuyasu, Takamitsu Tanaka, Takeko Ishikawa The Journal of Dermatology.2024; 51(9): 1216. CrossRef
Immune system dysregulation in the pathogenesis of non-alcoholic steatohepatitis: unveiling the critical role of T and B lymphocytes Merve Cebi, Yusuf Yilmaz Frontiers in Immunology.2024;[Epub] CrossRef
Evolution of FIB-4 score in SpA and PsA patients taking anti-TNF or anti-IL17 Frank Verhoeven, Clément Prati, Vincent Di Martino, Thierry Thevenot, Céline Demougeot, Daniel Wendling, Delphine Weil-Verhoeven Joint Bone Spine.2024; 91(6): 105763. CrossRef
Application of graph theory in liver research: A review Xumei Hu, Longyu Sun, Rencheng Zheng, Xueqin Xia, Meng Liu, Weibo Chen, Xinyu Zhang, Chengyan Wang Portal Hypertension & Cirrhosis.2024; 3(4): 234. CrossRef
Real-World Screening Data for Liver Fibrosis in Psoriasis Patients Treated with Biologics Susumu Ichiyama, Michiko Ito, Saeko Ozaki, Taeang Arai, Masanori Atsukawa, Katsuhiko Iwakiri, Teppei Hagino, Toshihiko Hoashi, Naoko Kanda, Hidehisa Saeki Journal of Nippon Medical School.2024; 91(6): 534. CrossRef
The beneficial impact of metabolic dysfunction‐associated fatty liver disease on lenvatinib treatment in patients with non‐viral hepatocellular carcinoma Shigeo Shimose, Atsushi Hiraoka, Andrea Casadei‐Gardini, Tsubasa Tsutsumi, Dan Nakano, Hideki Iwamoto, Fujimasa Tada, Margherita Rimini, Masatoshi Tanaka, Takuji Torimura, Hideya Suga, Hideko Ohama, Valentina Burgio, Takashi Niizeki, Etsuko Moriyama, Hiro Hepatology Research.2023; 53(2): 104. CrossRef
The Inter-Organ Crosstalk Reveals an Inevitable Link between MAFLD and Extrahepatic Diseases Tsubasa Tsutsumi, Dan Nakano, Ryuki Hashida, Tomoya Sano, Machiko Kawaguchi, Keisuke Amano, Takumi Kawaguchi Nutrients.2023; 15(5): 1123. CrossRef
Mechanism-based target therapy in primary biliary cholangitis: opportunities before liver cirrhosis? Yushu Yang, XiaoSong He, Manuel Rojas, Patrick S. C. Leung, Lixia Gao Frontiers in Immunology.2023;[Epub] CrossRef
Ultrasonographic Assessment of Tissue Stiffness: Recent Progress in Transient Elastography and Shear Wave Elastography in the Liver and Various Organs MASAHITO NAKANO, RYOKO KUROMATSU, TAKUMI KAWAGUCHI The Kurume Medical Journal.2023; 70(1.2): 1. CrossRef
Gut dysbiosis in nonalcoholic fatty liver disease: pathogenesis, diagnosis, and therapeutic implications Jie Fang, Chen-Huan Yu, Xue-Jian Li, Jin-Mei Yao, Zheng-Yu Fang, Soo-Hyun Yoon, Wen-Ying Yu Frontiers in Cellular and Infection Microbiology.2022;[Epub] CrossRef
Liver fibrosis prevalence and risk factors in patients with psoriasis: A systematic review and meta-analysis Tanat Yongpisarn, Amornrut Namasondhi, Wimolsiri Iamsumang, Ploysyne Rattanakaemakorn, Poonkiat Suchonwanit Frontiers in Medicine.2022;[Epub] CrossRef
We present a case of a 65-year-old man with psoriasis who developed autoimmune hepatitis (AIH) without receiving immunosuppressive therapy with either anti-tumor necrosis factor-α or methotrexate. The AIH had completely resolved at 2 months after prednisolone and azathioprine therapy. This case confirms the need to consider AIH in psoriasis patients who experience new elevations in liver enzymes. To our knowledge, this is first description of the development of AIH in an immunosuppressant-naïve patient with psoriasis.
Citations
Citations to this article as recorded by
Molecular mechanisms behind the inhibitory effects of ginsenoside Rg3 on hepatic fibrosis: a review Zhao-feng Tian, Rui-yi Hu, Zi Wang, Ya-jun Wang, Wei Li Archives of Toxicology.2025; 99(2): 541. CrossRef
Skin Manifestations Associated with Autoimmune Liver Diseases: a Systematic Review Benedetta Terziroli Beretta-Piccoli, Pietro Invernizzi, M. Eric Gershwin, Carlo Mainetti Clinical Reviews in Allergy & Immunology.2017; 53(3): 394. CrossRef
Methotrexate (MTX) has been widely used in the treatment of psoriasis and rheumatoid arthritis. But prolonged use of MTX can induce hepatic fibrosis and even cirrhosis. To date, in Korea, there have been very few reports on hepatotoxicity due to MTX, and no report on biopsy-proven chronic active hapatitis. We report one patient who developed chronic acitve hepatitis while taking long- term daily dose of MTX(10mg per day) for psoriasis for a prolonged period.
First
Prev
